Jihane N Benhammou
Overview
Explore the profile of Jihane N Benhammou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benhammou J, Sinnett-Smith J, Pisegna J, Rozengurt E
Gastro Hep Adv
. 2024 Aug;
2(2):232-241.
PMID: 39132609
Nonalcoholic fatty liver disease has reached pandemic proportions with one of its most consequential complications being hepatocellular carcinoma (HCC). Nonalcoholic fatty liver disease-related HCC is becoming the leading indication for...
2.
Parikh N, Jones P, Salgia R, Bhan I, Grinspan L, Jou J, et al.
Clin Gastroenterol Hepatol
. 2024 Aug;
23(2):281-290.e4.
PMID: 39089513
Background & Aims: Noninvasive variceal risk stratification systems have not been validated in patients with hepatocellular carcinoma (HCC), which presents logistical barriers for patients in the setting of systemic HCC...
3.
Wang D, Baghoomian A, Zhang Z, Cui Y, Whang E, Li X, et al.
J Clin Invest
. 2024 Jul;
134(17).
PMID: 39058558
No abstract available.
4.
Lee S, Garske K, Arasu U, Kar A, Miao Z, Alvarez M, et al.
EBioMedicine
. 2024 Jul;
106:105232.
PMID: 38991381
Background: Abdominal obesity increases the risk for non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: To elucidate the directional cell-type level biological mechanisms...
5.
Wang D, Baghoomian A, Zhang Z, Cui Y, Whang E, Li X, et al.
bioRxiv
. 2024 Jul;
PMID: 38948798
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic-associated fatty liver disease (MAFLD), is the most common liver disease worldwide. The progression to fibrosis, occurring against a backdrop of hepatic steatosis...
6.
Yang J, Chittajallu P, Benhammou J, Patel A, Pisegna J, Tabibian J, et al.
Dig Dis Sci
. 2024 Jun;
69(8):3079-3084.
PMID: 38896359
Background: Treatment with atezolizumab and bevacizumab has become standard of care for advanced unresectable hepatocellular carcinoma (HCC) but carries an increased gastrointestinal bleeding risk. Therefore, patients are often required to...
7.
Pham N, Benhammou J
Semin Liver Dis
. 2024 May;
44(2):191-208.
PMID: 38701856
Chronic liver disease (CLD) is a major contributor to global mortality, morbidity, and healthcare burden. Progress in pharmacotherapeutic for CLD management is lagging given its impact on the global population....
8.
Benhammou J, Leng M, Shah S, Cholankeril G, Dong T, Patel A, et al.
JAMA Netw Open
. 2023 Dec;
6(12):e2346380.
PMID: 38048128
Importance: Hepatocellular carcinoma (HCC) and its mortality are on the rise. Viral hepatitis and alcohol are leading risk factors; however, other risk factors among veterans are less defined, including Agent...
9.
Bangaru S, Sundaresh R, Lee A, Prause N, Hao F, Dong T, et al.
Dig Dis Sci
. 2023 Oct;
68(12):4474-4484.
PMID: 37864738
Background And Aims: Nonalcoholic fatty liver disease (NAFLD) has reached pandemic proportions. Early detection can identify at-risk patients who can be linked to hepatology care. The vibration-controlled transient elastography (VCTE)...
10.
Benhammou J, Qiao B, Ko A, Sinnett-Smith J, Pisegna J, Rozengurt E
Am J Physiol Gastrointest Liver Physiol
. 2023 Jun;
325(3):G239-G250.
PMID: 37366601
Hepatocellular carcinoma (HCC) is the third leading cause of liver-related death. Lipophilic statins have been associated with a decrease in HCC incidence, raising the possibility of their use as chemoprevention...